A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Running, not enrolling · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Hereditary Hemorrhagic Telangiectasia
In brief
The purpose of this study is to: * evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of single ascending doses of ALN-6400 in healthy volunteers * evaluate the efficacy, safety, tolerability and PD of multiple doses of ALN-6400 in adult patients with HHT
Key facts
- Study ID
- NCT06659640
- Run by
- Alnylam Pharmaceuticals
- People needed
- 89
- Starts
- 2024-11-07
- Expected to finish
- 2028-06-22
- Last updated by the study team
- 2026-07-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
Where it is running
- Clinical Trial Site — Birmingham, Alabama, United States
- Clinical Trial Site — Cypress, California, United States
- Clinical Trial Site — Gainesville, Florida, United States
- Clinical Trial Site — Indianapolis, Indiana, United States
- Clinical Trial Site — Boston, Massachusetts, United States
- Clinical Trial Site — Rochester, Minnesota, United States
- Clinical Trial Site — St Louis, Missouri, United States
- Clinical Trial Site — Chapel Hill, North Carolina, United States
- Clinical Trial Site — Camperdown, Australia
- Clinical Trial Site — Parkville, Australia
- Clinical Trial Site — Mount Royal, Canada
- Clinical Trial Site — Toronto, Canada
- Clinical Trial Site — Bordeaux, France
- Clinical Trial Site — Bron, France
- Clinical Trial Site — Homburg, Germany
- Clinical Trial Site — L'Hospitalet de Llobregat, Spain
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.